Pfizer Inc (PFE.N) said on Monday it has started a large study testing its investigational oral antiviral drug for the prevention of COVID-19 infection among those who have been exposed to the virus. The drugmaker and its rivals, includi..
The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that have yet to be certified by peer review. Vaccinated pregnant women pass antibodies to babies P..
Hairdressers in parts of the UK are reporting clients having new allergic reactions, like rashes and burns, to hair dye after contracting coronavirus. Scientists at Imperial College London are now researching how the disease could be reprogramming..
The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that have yet to be certified by peer review. Severe COVID-19 may "trip off" immune self-att..
Johnson & Johnson (JNJ.N) said Tuesday a second shot of its COVID-19 vaccine given about two months after the first increased its effectiveness to 94% in the United States against moderate to severe forms of the disease. That compare..
French artificial heartmaker Carmat (ALCAR.PA) announced on Tuesday that it had carried out the first implant of its Aeson artificial heart in a woman. The company said the procedure had been performed at the UofL Health - Jewish Hospita..
The Primary Health Care Corporation (PHCC) called for increased attention to mental health in light of the changes that accompanied the outbreak of COVID-19 pandemic, as human societies and their members faced a set of challenges, fears and psycholog..
Doha, September 20 (QNA) - Sidra Medicine, a member of Qatar Foundation for Education, Science and Community Development, is celebrating Apheresis Awareness Day -which falls on Sep. 21 annually- with the theme "Spinning to Advance Apheresis Medi..
Pfizer and BioNTech on Monday said trial results showed their coronavirus vaccine is safe and produces a robust immune response in children aged five to 11, adding that they would seek regulatory approval shortly. The vaccine would be administered..